Loading institutional data...
Loading institutional data...
Held by 223 of 5,944 reporting institutions (92th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$114M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -10215%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $64M covers all $58M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2014-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 46th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 4.3× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 68.1 | 62.0 | 58.7 | 54.9 | 61.8 | 73.7 | 75.8 | 71.4 |
| Gross Profit | 31.9 | 38.0 | 41.3 | 45.1 | 38.2 | 26.3 | 24.2 | 28.6 |
| R&D | 79.6 | 65.6 | 81.3 | 86.5 | 150.4 | 93.3 | 87.6 | 60.8 |
| SG&A | 80.7 | 83.1 | 92.3 | 95.1 | 125.4 | 84.7 | 113.6 | 88.4 |
| Operating Income | -128.4 | -110.6 | -132.3 | -161.2 | -239.4 | -166.8 | -308.0 | -346.2 |
| Income Tax | — | — | — | -71.8 | 0.0 | -5.7 | 0.2 | 0.2 |
| Net Income | -130.4 | -92.6 | 37.3 | -138.8 | -244.9 | -153.0 | -201.2 | -341.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PACB: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160.0M 100.0% | $154.0M 100.0% | $200.5M 100.0% | $128.3M 100.0% | $130.5M 100.0% | $78.9M 100.0% | $90.9M 100.0% | $78.6M 100.0% | $93.5M 100.0% | $90.7M 100.0% |
| Cost of Revenue | $114.2M 71.4% | $116.7M 75.8% | $147.7M 73.7% | $79.3M 61.8% | $71.7M 54.9% | $46.3M 58.7% | $56.3M 62.0% | $53.5M 68.1% | $58.8M 62.9% | $46.6M 51.3% |
| Cost of Products | — | — | — | — | — | — | — | — | $42.9M 45.9% | $34.5M 38.0% |
| Gross Profit | $45.8M 28.6% | $37.3M 24.2% | $52.8M 26.3% | $49.0M 38.2% | $58.9M 45.1% | $32.6M 41.3% | $34.6M 38.0% | $25.1M 31.9% | $34.7M 37.1% | $44.2M 48.7% |
| Research & Development | $97.3M 60.8% | $134.9M 87.6% | $187.2M 93.3% | $193.0M 150.4% | $112.9M 86.5% | $64.2M 81.3% | $59.6M 65.6% | $62.6M 79.6% | $65.3M 69.9% | $67.6M 74.5% |
| Selling, General & Admin | $141.5M 88.4% | $175.0M 113.6% | $169.8M 84.7% | $160.9M 125.4% | $124.1M 95.1% | $72.8M 92.3% | $75.5M 83.1% | $63.5M 80.7% | $59.1M 63.3% | $47.8M 52.7% |
| Total Operating Expenses | $599.6M 374.8% | $511.6M 332.2% | $387.2M 193.1% | $356.2M 277.6% | $269.3M 206.3% | $137.0M 173.6% | $135.1M 148.7% | $126.1M 160.4% | $124.4M 133.1% | $115.4M 127.2% |
| Operating Income | -$553.9M -346.2% | -$474.3M -308.0% | -$334.5M -166.8% | -$307.2M -239.4% | -$210.4M -161.2% | -$104.4M -132.3% | -$100.5M -110.6% | -$101.0M -128.4% | -$89.8M -96.1% | -$71.2M -78.5% |
| Interest Expense | $7.0M 4.3% | $13.4M 8.7% | $14.3M 7.2% | $14.7M 11.4% | $12.5M 9.6% | $267K 0.3% | $2.6M 2.9% | $2.4M 3.1% | $2.9M 3.1% | $3.2M 3.6% |
| Other Income (Expense), net | $14.8M 9.2% | $23.8M 15.4% | $32.7M 16.3% | $7.6M 6.0% | $93K 0.1% | $2.1M 2.6% | $1.0M 1.1% | $848K 1.1% | $516K 0.6% | $103K 0.1% |
| Pretax Income | -$546.1M -341.3% | -$309.5M -201.0% | -$318.2M -158.7% | -$314.2M -244.9% | -$274.9M -210.6% | $29.4M 37.3% | -$84.1M -92.6% | — | — | — |
| Income Tax Expense | $318K 0.2% | $316K 0.2% | -$11.4M -5.7% | $0 0.0% | -$93.6M -71.8% | — | — | — | — | — |
| Net Income | -$546.4M -341.5% | -$309.9M -201.2% | -$306.7M -153.0% | -$314.2M -244.9% | -$181.2M -138.8% | $29.4M 37.3% | -$84.1M -92.6% | -$102.6M -130.4% | -$92.2M -98.6% | -$74.4M -82.0% |
| Per Share | ||||||||||
| EPS (Basic) | $-1.82 | $-1.13 | $-1.21 | $-1.40 | $-0.89 | $0.18 | $-0.55 | $-0.76 | — | — |
| EPS (Diluted) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | — | — |
| Weighted Avg Shares (Basic) | 300.0M | 274.5M | 253.6M | 224.6M | 204.1M | 165.2M | 152.5M | 135.1M | — | — |
| Weighted Avg Shares (Diluted) | 300.0M | 288.4M | 253.6M | 224.6M | 204.1M | 175.0M | 152.5M | 135.1M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| PACB | $417M | — | — | 2.6× | 3.9% | 28.6% | -341% | -10215% | -10215% | — | 223 |
Peers = companies sharing PACB's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.